BioTelemetry MCOT Patch: 30-Day Continuous ECG for Arrhythmia Detection

When a two-week cardiac monitor is not enough, the BioTelemetry MCOT Patch extends the diagnostic window to 30 continuous days of real-time ECG surveillance.

Presented By Our Partners

In 2019, a landmark study published in the Journal of the American Heart Association analyzed over 90,000 patients monitored with mobile cardiac outpatient telemetry and found that extending monitoring duration beyond 14 days identified an additional 18% of clinically significant arrhythmias that shorter monitoring periods missed entirely. The finding confirmed what cardiologists had long suspected: many dangerous heart rhythm abnormalities are intermittent, unpredictable, and stubbornly elusive. A patient might wear a monitor for two weeks and experience no episodes, only to have a syncopal event the day after the device comes off.

This is the clinical problem the BioTelemetry MCOT Patch was designed to solve. Built by BioTelemetry, now a subsidiary of Philips, the MCOT (Mobile Cardiac Outpatient Telemetry) system delivers 30 days of continuous, real-time ECG monitoring with AI-powered arrhythmia detection and immediate clinician notification. It represents the most comprehensive ambulatory cardiac monitoring available outside of an inpatient setting, and it has become one of the most widely prescribed remote cardiac monitoring solutions in the United States.

What Is the BioTelemetry MCOT Patch?

The BioTelemetry MCOT Patch is an FDA-cleared ambulatory ECG monitor that records continuous single-lead electrocardiogram data for up to 30 days. Unlike traditional Holter monitors that simply record and store data for later analysis, the MCOT system operates as a real-time telemetry platform. The adhesive patch attaches to the chest and wirelessly transmits ECG data to a small companion device, which relays the signal through cellular connectivity to BioTelemetry’s monitoring center, staffed around the clock by certified cardiac technicians.

The system employs proprietary AI algorithms to detect clinically significant arrhythmias in real time, including atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, bradycardia, and prolonged pauses. When the algorithm identifies a potentially dangerous rhythm, it triggers an immediate alert to the monitoring center, where a technician reviews the strip and, if warranted, contacts the prescribing physician directly. This real-time escalation pathway distinguishes MCOT from patch monitors that store data for batch analysis after the monitoring period ends.

The device is prescribed through a physician order and is typically covered by Medicare and major commercial insurance plans. Out-of-pocket costs for patients vary based on insurance coverage but generally range from $0 to $500 depending on the plan and deductible status.

The Science Behind Continuous Cardiac Monitoring

The clinical value of extended cardiac monitoring rests on a simple epidemiological reality: atrial fibrillation, the most common sustained arrhythmia, affects an estimated 6 million Americans, yet a significant proportion of cases remain undiagnosed because episodes occur sporadically. The Framingham Heart Study established decades ago that atrial fibrillation increases stroke risk fivefold, and subsequent research has shown that even brief, asymptomatic episodes (so-called subclinical atrial fibrillation) carry meaningful thromboembolic risk.

A 2021 study published in Circulation by Russo et al. examined over 5,500 patients and found that subclinical atrial fibrillation detected by continuous monitoring was associated with a 2.5-fold increased risk of ischemic stroke, even when episodes lasted less than 24 hours. The implication is clear: finding these episodes before a stroke occurs is a matter of monitoring duration, not monitoring technology. The longer you look, the more you find.

The ASSERT trial, published in the New England Journal of Medicine, demonstrated that patients with implanted cardiac devices who experienced subclinical atrial tachyarrhythmias had a 2.49-fold increased risk of ischemic stroke or systemic embolism over a 2.5-year follow-up. This study helped establish the clinical principle that detecting even brief arrhythmia episodes has direct therapeutic consequences, primarily the initiation of anticoagulation therapy that can reduce stroke risk by 60% to 70%.

Remote patient monitoring with devices like the MCOT Patch has also demonstrated systemic benefits beyond arrhythmia detection. A 2020 analysis published in the Journal of Medical Internet Research found that remote cardiac monitoring reduced 30-day hospital readmission rates by 38% among heart failure patients, with the continuous data stream enabling earlier intervention before clinical deterioration reached the threshold requiring emergency care.

Within Healthcare Discovery‘s longevity framework, cardiovascular disease represents one of the Four Shadows, the primary chronic disease threats that stand between current health and the longevity breakthroughs arriving in the next decade. Early arrhythmia detection through extended monitoring is not merely diagnostic; it is preventive, enabling therapeutic interventions that can add years to both lifespan and healthspan.

What the MCOT Patch Does Well

The MCOT Patch’s primary advantage is its 30-day continuous monitoring window, which is twice the duration of the most widely used patch monitors. For patients with infrequent symptoms, those who experience palpitations or syncope only once or twice a month, this extended window dramatically increases the probability of capturing a diagnostic event. Published data from BioTelemetry’s clinical studies indicate that the MCOT system achieves a diagnostic yield of approximately 60% to 70% for patients referred for palpitation or syncope evaluation, compared to 30% to 40% for standard 24-hour to 48-hour Holter monitors.

The real-time monitoring capability is the second major differentiator. While patch monitors like the Zio Patch by iRhythm provide excellent data quality and longer wear times than traditional Holters, they operate in a store-and-forward model: data is analyzed after the patient returns the device. The MCOT system, by contrast, delivers real-time alerts that can reach a physician within minutes of a dangerous arrhythmia onset. For high-risk patients, particularly those with a history of ventricular tachycardia or unexplained syncope, this real-time capability can be clinically critical.

The Philips acquisition brought additional resources to the platform, integrating MCOT data into Philips’ broader remote patient monitoring ecosystem. Clinicians can access patient data through a centralized portal alongside other Philips monitoring devices, creating a more unified view of cardiac health over time.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The AI analysis engine processes ECG data continuously, applying algorithms trained on millions of previously analyzed cardiac strips. This reduces false-positive alert rates while maintaining high sensitivity for clinically significant events, a balance that directly affects the clinical utility of the monitoring program.

Pricing, Access, and Practical Realities

The BioTelemetry MCOT Patch operates within the clinical prescriber model, meaning patients access the device through a physician order rather than direct consumer purchase. This is not a device you buy off the shelf. A cardiologist, electrophysiologist, or sometimes a primary care physician determines that extended cardiac monitoring is clinically indicated, writes the prescription, and the monitoring service handles device delivery, setup instructions, and data collection.

Insurance coverage is the primary payment pathway. Medicare covers MCOT monitoring under established CPT codes for mobile cardiac telemetry, and most major commercial insurance plans follow suit. Patient out-of-pocket costs depend entirely on insurance plan design, including deductible status, copay structure, and whether the monitoring service is in-network. Typical patient responsibility ranges from $0 (for patients who have met their deductible) to approximately $300 to $500 for those with high-deductible plans.

The device is HSA and FSA eligible when prescribed by a physician, which provides a tax-advantaged payment pathway for patients with health savings or flexible spending accounts.

It is important to note that the MCOT Patch is FDA cleared as an ambulatory ECG monitoring system, not as a diagnostic tool in isolation. The device records and transmits data; diagnosis remains the responsibility of the interpreting physician. The FDA clearance covers the device’s ability to accurately record and transmit ECG signals, not its ability to replace clinical judgment.

Who It Is Best For

The MCOT Patch is most appropriate for patients with infrequent but potentially serious cardiac symptoms. The primary clinical indications include evaluation of unexplained syncope (fainting), palpitations that occur less frequently than once every two weeks, post-ablation monitoring for atrial fibrillation recurrence, cryptogenic stroke workup (searching for occult atrial fibrillation as a stroke cause), and surveillance of patients with known arrhythmia risk factors who require documentation before initiating or adjusting antiarrhythmic or anticoagulant therapy.

Patients who have already worn a shorter-duration monitor (14-day patch or 24-hour Holter) without capturing a diagnostic event are ideal candidates for the 30-day MCOT extension. The longer window and real-time alerting justify the increased monitoring intensity for these diagnostically challenging cases.

Patients with daily or near-daily symptoms may not need the MCOT’s extended duration. A standard 14-day patch monitor or even a 24-hour to 48-hour Holter may capture sufficient data at lower cost. Similarly, patients seeking consumer-grade heart rhythm awareness rather than clinical arrhythmia workup would be better served by consumer wearables like the Apple Watch or Oura Ring, which offer ongoing rhythm notifications without the clinical monitoring infrastructure.

How It Compares

The most direct competitor is the Zio Patch by iRhythm Technologies, which offers 14 days of continuous ECG recording with AI-powered analysis. The Zio Patch has accumulated an extensive clinical validation portfolio and is the most widely prescribed single-lead ambulatory monitor in the United States. However, it operates as a store-and-forward system: data is analyzed after the monitoring period ends, not in real time. For patients who need real-time arrhythmia notification, the MCOT’s telemetry capability is a meaningful clinical advantage.

Implantable loop recorders (ILRs) such as the Medtronic LINQ II represent the other end of the monitoring spectrum. These devices are surgically implanted beneath the skin and can monitor for up to three years, making them the gold standard for extremely infrequent arrhythmias. However, ILR implantation is a minor surgical procedure with associated risks, costs typically exceeding $10,000, and a longer path to clinical decision-making. The MCOT occupies the middle ground: longer than a patch monitor, less invasive than an implant.

Consumer wearables, including the Apple Watch with its FDA-cleared irregular rhythm notification and single-lead ECG, serve a fundamentally different purpose. These devices provide screening-level awareness for a general population, while the MCOT provides diagnostic-level monitoring for patients with known or suspected cardiac disease. The clinical-grade data quality, continuous professional monitoring, and real-time escalation protocols place the MCOT in a different clinical category entirely.

Limitations and Open Questions

The MCOT Patch requires a physician prescription, which creates an access barrier for patients who suspect they have arrhythmias but have not yet entered the clinical evaluation pathway. The device is not available for self-directed monitoring or wellness optimization.

Skin irritation from the adhesive over a 30-day wear period is a common patient complaint. Some patients develop contact dermatitis that requires early device removal, which can compromise the monitoring window. Adhesive technology has improved over successive device generations, but the fundamental challenge of maintaining skin contact for a month remains.

The real-time monitoring model requires cellular connectivity, which means the companion transmitter device must maintain a wireless signal. Patients in areas with poor cellular coverage may experience data gaps that reduce monitoring completeness.

Data ownership and portability raise important questions. ECG data generated by the MCOT system is stored within BioTelemetry’s (Philips’) infrastructure. Patients and referring physicians receive reports, but the raw data is not typically available for export to other monitoring platforms or personal health records. As remote patient monitoring becomes more prevalent, interoperability standards will need to evolve.

What This Means for Your Health

Cardiovascular disease remains the leading cause of death globally, and arrhythmias are among the most treatable cardiovascular conditions when detected early. The clinical evidence is unambiguous: finding atrial fibrillation before a stroke occurs, rather than after, changes outcomes dramatically. Anticoagulation therapy initiated on the basis of arrhythmia detection reduces stroke risk by 60% to 70%, a degree of risk reduction that few medical interventions can match.

The BioTelemetry MCOT Patch represents the current standard for extended ambulatory cardiac monitoring with real-time clinical oversight. For patients in the diagnostic gray zone, those with concerning symptoms but no captured arrhythmia, 30 days of continuous monitoring provides the longest non-invasive diagnostic window available. It bridges the gap between shorter patch monitors and implantable devices, serving patients whose clinical picture demands more data before therapeutic decisions can be made.

Within the framework of HealthcareDiscovery.ai’s Five Pillars, cardiac monitoring intersects most directly with Movement and Breathwork. Heart rate variability, one of the signals captured by continuous ECG, reflects autonomic nervous system balance, which is modulated by exercise, breathing practices, sleep quality, and stress management. Understanding your cardiac rhythm is not merely about disease detection; it is about understanding how your daily practices shape the electrical behavior of the organ that determines your longevity.

The broader trajectory of remote cardiac monitoring points toward a future where continuous heart rhythm data becomes as routine as blood pressure measurement. The BioTelemetry MCOT Patch is a clinical-grade tool designed for a specific diagnostic purpose, but the principles it embodies (continuous measurement, AI-assisted analysis, real-time clinical response) are the same principles driving the entire field of precision cardiovascular medicine forward.

Frequently Asked Questions

What is the BioTelemetry MCOT Patch and how does it work?
The BioTelemetry MCOT Patch is an FDA-cleared ambulatory ECG monitor that records continuous heart rhythm data for up to 30 days. The adhesive chest patch wirelessly transmits ECG signals to a companion device, which relays data via cellular connectivity to a 24/7 monitoring center. AI algorithms analyze the data in real time, and certified cardiac technicians review flagged events. If a clinically significant arrhythmia is detected, the monitoring center contacts the prescribing physician directly, enabling rapid clinical response.

How much does the BioTelemetry MCOT Patch cost?
The MCOT Patch is accessed through a physician prescription and is typically covered by Medicare and major commercial insurance plans. Patient out-of-pocket costs range from $0 to approximately $500 depending on insurance plan design, deductible status, and network participation. The device is HSA and FSA eligible when prescribed by a physician. There is no subscription fee; the monitoring service is included in the prescribed monitoring period.

How does the MCOT Patch differ from the Zio Patch?
The two key differences are monitoring duration and real-time capability. The MCOT Patch monitors for 30 continuous days compared to the Zio Patch’s 14 days, and the MCOT provides real-time arrhythmia alerts through its telemetry monitoring center, while the Zio Patch stores data for batch analysis after the monitoring period ends. For patients with very infrequent symptoms or those requiring immediate notification of dangerous rhythms, the MCOT’s extended duration and real-time monitoring offer clinical advantages.

Is the BioTelemetry MCOT Patch FDA cleared?
Yes. The MCOT system is FDA cleared as an ambulatory ECG monitoring device under the mobile cardiac telemetry category. This clearance covers the device’s ability to accurately record, transmit, and facilitate analysis of continuous ECG data. The FDA clearance does not mean the device itself makes diagnoses; rhythm interpretation and clinical decision-making remain the responsibility of the treating physician.

Can I shower or exercise while wearing the MCOT Patch?
The MCOT Patch is designed for continuous wear during normal daily activities. Most versions are water-resistant for brief water exposure such as showering, though prolonged submersion (swimming, baths) is generally not recommended. Light to moderate exercise is typically permitted, though patients should follow their physician’s specific activity guidelines. The adhesive is designed to maintain contact during physical activity, though excessive sweating may require additional skin preparation or adhesive reinforcement.

Who should consider the MCOT Patch instead of a consumer heart monitor?
The MCOT Patch is appropriate for patients with specific clinical indications, including unexplained fainting, infrequent palpitations, post-ablation monitoring, or cryptogenic stroke workup. If a shorter monitor (Holter or 14-day patch) failed to capture a diagnostic event, the 30-day MCOT is the logical next step. Consumer wearables like the Apple Watch provide screening-level rhythm notifications for a general population but do not deliver the continuous clinical-grade ECG data, real-time professional monitoring, or diagnostic reporting required for clinical decision-making in patients with known or suspected heart disease.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.